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hs- CRP: Highly sensitive C-reactive protein
ICS: Inhaled corticosteroid
IL: Interleukin
LABA: Long acting beta agonist
PaCO2: Pressure of arterial carbondioxid
PaO2: Pressure of arterial oxygen
SABA: Short acting beta agonist
SCS: Systemic corticosteroid
TNF: Tumor necrosis factor
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